Gilead Sciences Inc.’s cancer drug Trodelvy was approved by US regulators to treat another type of breast cancer, providing an additional option to thousands suffering from the disease.
The Food and Drug Administration cleared the medicine for some people with a common type of spreading breast cancer who have tried at least three other therapies, Gilead said in a press release Friday. Gilead estimates that about 6,000 to 8,000 people in the US fall into that category this year, a company spokesperson said.
“There is a significant human need here,” said Gilead Chief Executive Officer Daniel O’Day said in ...
